Procter & Gamble Health Intrinsic Value
PGHL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹4065.60 | ₹3252.48 - ₹4878.72 | -27.1% | EPS: ₹184.80, Sector P/E: 22x |
| Book Value Method | asset | ₹1115.80 | ₹1004.22 - ₹1227.38 | -80.0% | Book Value/Share: ₹315.88, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1673.70 | ₹1506.33 - ₹1841.07 | -70.0% | Revenue/Share: ₹765.29, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2535.00 | ₹2281.50 - ₹2788.50 | -54.6% | EBITDA: ₹431.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2231.60 | ₹1785.28 - ₹2677.92 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1825.36 | ₹1642.82 - ₹2007.90 | -67.3% | EPS Growth: 12.3%, Fair P/E: 9.9x |
| Growth Adjusted P/E | growth | ₹2822.33 | ₹2540.10 - ₹3104.56 | -49.4% | Revenue Growth: 3.6%, Adj P/E: 15.3x |
| ROE Based Valuation | profitability | ₹2889.41 | ₹2600.47 - ₹3178.35 | -48.2% | ROE: 57.2%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1673.70 | ₹1506.33 - ₹1841.07 | -70.0% | EPS: ₹184.80, BVPS: ₹315.88 |
Want to compare with current market value? Check PGHL share price latest .
Valuation Comparison Chart
PGHL Intrinsic Value Analysis
What is the intrinsic value of PGHL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Procter & Gamble Health (PGHL) is ₹2231.60 (median value). With the current market price of ₹5579.00, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹1115.80 to ₹4065.60, indicating ₹1115.80 - ₹4065.60.
Is PGHL undervalued or overvalued?
Based on our multi-method analysis, Procter & Gamble Health (PGHL) appears to be trading above calculated value by approximately 60.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.52 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.48 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 57.2% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 32.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.64x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Procter & Gamble Health
Additional stock information and data for PGHL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹169 Cr | ₹169 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹228 Cr | ₹225 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹236 Cr | ₹225 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹170 Cr | ₹157 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹247 Cr | ₹231 Cr | Positive Free Cash Flow | 8/10 |